Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long- Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia

Last modified: December 1, 2021
You are here:
Estimated reading time: 1 min
Research Article: Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
Author: Thanompong Sathienluckana, Pornyupa Tiangpattanawong, Karnpreena Chaiyasukthananoan, Pannapat Jittayanan, Hathaipat Sawetwangsing and Punyawee Puchsaka
Email: thanompong.sat@siam.edu
Department|Faculty: Faculty of Pharmacy,  Siam University, Bangkok 10160
Published: Schizophrenia Research and Treatment Vol.2021, Article number: 8403986 Page.1-6

Citation

Sathienluckana T., Tiangpattanawong P., Chaiyasukthananoan K., Jittayanan P., Sawetwangsing H. & Puchsaka P. (2021). Comparison of efficacy and safety between long-acting injectable antipsychotic monotherapy and combination of long-acting injectable and oral antipsychotics in patients with schizophrenia. Schizophrenia Research and Treatment, 2021(8403986), 1-6. Retrieved from https://doi.org/10.1155/2021/8403986


ABSTRACT

Background. Long-acting injectable (LAI) antipsychotics are used as a monotherapy in patients with schizophrenia. However, the combination of LAI and oral antipsychotics is commonly used in clinical practice, despite there being very limited studies investigating the efficacy and safety of this combination compared with LAI antipsychotic monotherapy. Objective. To study the efficacy and safety of LAI antipsychotic monotherapy compared with the combination of LAI and oral antipsychotics inpatients with schizophrenia. Methods. This study was a retrospective cohort study, which classified eligible patients into two groups: the LAI antipsychotic monotherapy group and the combination of LAI and oral antipsychotic group. The primary outcome was hospitalization between groups. The duration of the study was 2 years. Results. In total, 86 patients completed the study and were analysed (LAI antipsychotic monotherapy group: n = 25; combination of LAI and oral antipsychotic group: n =61). There was no significant difference in hospitalization between the two groups (P = 1:000). For other outcomes, there were also no significant differences in both all-cause discontinuation (P = 0:667) and adverse drug reactions (P = 0:732) between the two groups. Conclusion. The efficacy and safety of LAI antipsychotic monotherapy appeared similar to the combination of LAI and oral antipsychotics in patients with schizophrenia. Therefore, the combination of LAI and oral antipsychotics, which is commonly used in clinical practice, may not be necessary.

Keywords:  Efficacy, Long-acting injectable, Safety, Schizophrenia, Second-generation antipsychotics.


Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia

Faculty of Pharmacy, Siam University, Bangkok, Thailand

Tags:
Was this article helpful? บทความนี้เป็นประโยชน์หรือไม่?
ไม่ / Dislike 0
Views: 24
Previous: ปัจจัยที่เกี่ยวข้องกับการตั้งครรภ์ที่ไม่พึงประสงค์ของสตรีวัยรุ่นที่มาฝากครรภ์ โรงพยาบาลกระทุ่มแบน จ.สมุทรสาคร
Next: Variation of Autonomic Nervous System Function by Age and Gender in Thai Ischemic Stroke Patients